Drug survival of metformin in patients with hidradenitis suppurativa

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Autores
SENENT-VALERO, Marina
JARA-RICO, Noelia
SIVERA, Francisca
PASCUAL, Jose C.
Citação
BRITISH JOURNAL OF DERMATOLOGY, v.190, n.1, p.125-127, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Despite there being published studies on the survival of oral retinoids and biological drugs in people with hidradenitis suppurativa (HS), there is little scientific evidence on the use of metformin in this setting. We conducted a single-centre, retrospective cohort study in Spain, between January 2015 and December 2021 to determine the drug survival of metformin at 12 months in people with HS in a real-world setting. We concluded that drug survival of metformin is relatively long: half the patients were still on the drug after 1 year of treatment and one in five patients were still on the drug after 2 years.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/58967
Referências
  1. Badr D, 2013, J EUR ACAD DERMATOL, V27, P1329, DOI 10.1111/jdv.12116
  2. Bouwman K, 2022, AM J CLIN DERMATOL, V23, P905, DOI 10.1007/s40257-022-00725-9
  3. Ingram JR, 2019, BRIT J DERMATOL, V180, P1009, DOI 10.1111/bjd.17537
  4. Jennings L, 2020, J DERMATOL TREAT, V31, P261, DOI 10.1080/09546634.2019.1592100
  5. Prens LM, 2021, BRIT J DERMATOL, V185, P177, DOI 10.1111/bjd.19863
  6. Ring HC, 2022, JAMA DERMATOL, V158, P184, DOI 10.1001/jamadermatol.2021.4805
  7. Verdolini R, 2013, J EUR ACAD DERMATOL, V27, P1101, DOI 10.1111/j.1468-3083.2012.04668.x
  8. Vilanova I, 2018, J EUR ACAD DERMATOL, V32, P820, DOI 10.1111/jdv.14894

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPR